when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Oncology · news · pharmadog

← back to Oncology

News · Oncology

1,499 stories

May 7, 26HERIZON-GEA-01 Study Design, Geographic Distribution, and PD-L1 Testing Considerationsonclive

May 7, 26Integrating Evidence and Identifying Future Research Needs in Metastatic Castration Sensitive Prostate Cancer (mCSPC)onclive

May 7, 26Co-Occurring Mutations in NSCLC: Influence on Prognosis and Immunotherapy Responseonclive

May 7, 26Evaluating Observational and Propensity Matched Studies in Metastatic Castration Sensitive Prostate Cancer (mCSPC)onclive

May 7, 26Reigniting Your Curiosity During Fellowshiponclive

May 7, 26STAT+: FDA to reconsider treatment for rare cancer after its surprise rejectionstat

May 7, 26Hospital shootings steadily increased since 2000stat

May 7, 26STAT+: Next-gen Duchenne drug from Entrada disappointsstat

May 7, 26STAT+: Color me skeptical: Drinking gold is not an ALS curestat

May 6, 26MANEUVER Trial Underscores Potential Paradigm Shift Toward Targeted Approaches in TGCTonclive

May 6, 26STAT+: Oregon hospitals won’t outsource to national physician chain after allstat

May 6, 26Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinomaonclive

May 6, 26Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Canceronclive

May 6, 26Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLConclive

May 6, 26Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myelomaonclive

May 6, 26BeOne culls five cancer programs and an autoimmune Phase 2endpoints

May 6, 26FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLConclive

May 6, 26Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Canceronclive

May 6, 26Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphomaonclive

May 6, 26Dr Sznol on Biomarkers of Response in Metastatic Melanomaonclive

May 6, 26Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discoveryonclive

May 6, 26STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’stat

May 6, 26STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human diseasestat

May 6, 26Avalo shares spike on skin drug data; BioNTech to cut staffbiopharma dive

May 6, 26ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Goonclive

May 6, 26Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Durationonclive

May 6, 26Disease Assessment and Mutational Testing in Progressive CLLonclive

May 6, 26Clinical Scenario Presentation and Treatment Approach for Progressive Diseaseonclive

May 6, 26Dr Pant on the Mechanism of Action of Daraxonrasib in PDAConclive

May 6, 26Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026onclive

← prevpage 47 of 50next →